Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators’ review time only one benefitnews2021-11-01T13:42:10+00:00November 1st, 2021|Fierce Pharma|
Novartis keeps the leukemia innovation coming with FDA approval for Gleevec follow-on Scemblix as Tasigna patent cliff nearsnews2021-11-01T11:03:35+00:00November 1st, 2021|Fierce Pharma|
Novo Nordisk casts Queen Latifah in TV-themed awareness campaign for obesitynews2021-10-29T21:31:31+00:00October 29th, 2021|Fierce Pharma|
Pfizer’s COVID vaccine for younger kids meets FDA bar, with CDC panel next week being key to wide rolloutnews2021-10-29T20:04:56+00:00October 29th, 2021|Fierce Pharma|
Seagen stands by newly acquired HER2 breast cancer drug despite competition from AstraZeneca-Daiichi’s Enhertunews2021-10-29T19:38:36+00:00October 29th, 2021|Fierce Pharma|
Even AbbVie CEO can’t confirm Rinvoq’s sales as FDA mulls JAK labelnews2021-10-29T15:49:13+00:00October 29th, 2021|Fierce Pharma|
AbbVie’s Vraylar turns in mixed results in depression, but pharma decides to file for approval anywaynews2021-10-29T14:23:23+00:00October 29th, 2021|Fierce Pharma|
Pacira panel takes on uncomfortable women’s health topics to help womennews2021-10-29T12:57:41+00:00October 29th, 2021|Fierce Pharma|
Resurgeant Veklury delivers Gilead $1.9 billion in sales and an earnings surprisenews2021-10-29T11:24:01+00:00October 29th, 2021|Fierce Pharma|
Resurgent Veklury delivers Gilead $1.9B in sales and an earnings surprisenews2021-10-29T11:24:01+00:00October 29th, 2021|Fierce Pharma|
